Published Online: Monday, March 1, 2004

Roche (Nutley, NJ) recently announced that the FDA has approved labeling for use of the prescription weight-loss medication Xenical (orlistat) in the management of obese adolescents aged 12 to 16 years. This approval offers physicians and parents of overweight and obese adolescents a safe and effective treatment option to help manage their weight. Xenical works locally in the stomach to prevent dietary fat absorption by approximately 30%. It helps the patient lose weight as well as maintain the weight loss. For more information, visit www.xenical.com.

Latest Articles
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
As a result of implementation difficulties, the FDA announced that it will extend the pharmacy certification deadline for the clozapine risk evaluation and mitigation strategy program.
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Latest Issues